The Valgent4 Protocol: Robust analytical and clinical validation of 11 HPV assays with genotyping on cervical samples collected in SurePath medium

Practically all cervical cancers are derived from an Human papillomavirus (HPV) infection [1 –3] and the causal relation is firmly established between the development of cervical cancer and at least 12HPV genotypes (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and HPV59, all group 1 carcinogens as classified by IARC) [1,2]. Evidence on the clinical value of HPV testing for triage of bo rderline cervical cytology and test of cure in women who have been treated for pre-invasive cervical lesions is today widely accepted [4–6].

Source: Journal of Clinical Virology - September 17, 2018 Category: Virology Authors: Jesper Bonde, Ditte M øller Ejegod, Kate Cuschieri, Joakim Dillner, Daniëlle A.M. Heideman, Wim Quint, Miguel Angel Pavon Ribas, Elizaveta Padalko, Irene Kraus Christiansen, Lan Xu, Marc Arbyn Source Type: research